Hiep Dang, DO
Family Medicine · Garden Grove, CANPI 1356328900
Payments from drug & device makers
Across 400 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Boehringer Ingelheim$830
- Gilead$768
- Lilly USA, LLC$727
- Novo Nordisk$717
- plus $4K from 20 others
What the payments were for
- Food & beverage$9,222100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,355 |
| AbbVie | 59 | $1,225 |
| Boehringer Ingelheim | 27 | $830 |
| Gilead | 28 | $768 |
| Lilly USA, LLC | 32 | $727 |
| Novo Nordisk | 26 | $717 |
| GSK | 26 | $598 |
| Bayer | 22 | $456 |
| Amgen | 11 | $440 |
| Amarin Pharma, Inc. | 30 | $397 |
| Pfizer | 14 | $343 |
| Merck | 14 | $245 |
| Sanofi-aventis U.S. LLC | 10 | $176 |
| Johnson & Johnson | 9 | $170 |
| Aimmune Therapeutics, Inc. | 8 | $153 |
| Exact Sciences | 6 | $148 |
| Nestle Healthcare Nutrition Inc. | 4 | $99 |
| Sumitomo Pharma America, Inc. | 3 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Genentech USA, Inc. | 3 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Novartis | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Theracosbio, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,228 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 211 | $224,572 |
| FarxigaDapagliflozin Propanediol | 120 | $116,838 |
| VemlidyTenofovir Alafenamide | 70 | $100,823 |
| VascepaIcosapent Ethyl | 97 | $61,238 |
| OzempicSemaglutide | 35 | $60,769 |
| TrulicityDulaglutide | 32 | $55,213 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $43,933 |
| JanuviaSitagliptin Phosphate | 43 | $39,413 |
| RybelsusSemaglutide | 28 | $38,800 |
| KerendiaFinerenone | 22 | $33,996 |
| EliquisApixaban | 26 | $24,829 |
| SynjardyEmpagliflozin/Metformin Hcl | 23 | $20,996 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $20,619 |
| ProliaDenosumab | 12 | $20,326 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $19,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $830 | $262,148247 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Crestor | $1,355 | $139,838166 claims |
| GileadVemlidy | $768 | $100,82370 claims |
| Novo NordiskOzempic, Rybelsus | $717 | $99,56863 claims |
| MerckJanumet, Januvia | $245 | $83,34678 claims |
| Lilly USA, LLCTrulicity | $727 | $55,21332 claims |
| BayerKerendia | $456 | $33,99622 claims |
| AbbVieCreon, Linzess | $1,225 | $31,12638 claims |
| PfizerEliquis | $343 | $24,82926 claims |
| AmgenProlia | $440 | $20,32612 claims |
| GSKTrelegy Ellipta | $598 | $7,64613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Garden Grove
- Michael DaoGarden Grove$843K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.